Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant

The pharma also warns that an FDA complete response letter could be coming for its supplemental NDA to add atopic dermatitis to the JAK1 inhibitor’s label.

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV - Image
Lilly may be backing away from label expansion plans for Olumiant in atopic dermatitis

Eli Lilly and Company said on 28 January that it will cease development of oral JAK inhibitor Olumiant (baricitinib) in systemic lupus erythematosus (SLE) and may be nearing an impasse with the US Food and Drug Administration about a supplemental filing to add atopic dermatitis to the product’s label. For the atopic dermatitis indication, the pharma warned of the possibility of a complete response letter, with analysts suggesting that could end Lilly and partner Incyte Corporation's efforts with the drug in eczema.

Apparently, Lilly and Incyte’s lack of “alignment” with the FDA on the supplemental new drug application (sNDA) centers on the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.